Dianthus Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- None.
- None.
NEW YORK and and WALTHAM, Mass., March 07, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH) (“Dianthus”), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced that it granted an equity award on March 2, 2024, to a newly-hired, non-executive employee. The inducement grant was approved by the Company's independent Compensation Committee and was made as a material inducement to acceptance of employment with Dianthus in accordance with Nasdaq Listing Rule 5635(c)(4).
The inducement grant consists of a non-qualified stock option to purchase an aggregate of 30,000 shares of the Company's common stock with a 10-year term and an exercise price of
About Dianthus Therapeutics
Dianthus Therapeutics is a clinical-stage biotechnology company dedicated to designing and delivering novel, best-in-class monoclonal antibodies with improved selectivity and potency. Based in New York City and Waltham, Mass., Dianthus is comprised of an experienced team of biotech and pharma executives who are leading the development of next-generation antibody complement therapeutics, aiming to deliver transformative medicines for people living with severe autoimmune and inflammatory diseases.
To learn more, please visit www.dianthustx.com and follow us on LinkedIn.
Contact
Jennifer Davis Ruff
Dianthus Therapeutics
jdavisruff@dianthustx.com
FAQ
What is the recent announcement by Dianthus Therapeutics, Inc. (DNTH)?
What does the equity award granted by Dianthus Therapeutics, Inc. (DNTH) consist of?
What is the term of the stock option granted by Dianthus Therapeutics, Inc. (DNTH)?
How does the option vest for the equity award granted by Dianthus Therapeutics, Inc. (DNTH)?